Key takeaways
- 87.7% Fall in total monthly attacks at 6 months on lanadelumab, first national UK audit (62 patients, 16 centres)
- 93.5% Fall in total monthly attacks at 12 months in the same UK audit
- TA738 NICE recommendation (Oct 2021) for berotralstat in adults with ≥2 attacks/month, subject to a mandatory 3-month stop rule
NICE TA606 lanadelumab is delivering real-world outcomes that match its trial data — the benchmark berotralstat's NICE TA738 recommendation must sustain under its stop-rule review.
NICE TA606 (16 October 2019) recommended lanadelumab (Takhzyro, Takeda) for preventing recurrent attacks in people aged 12 and over who are eligible for preventive C1-inhibitor treatment under NHS England's commissioning policy, broadly two or more clinically significant attacks a week over 8 weeks despite oral prophylaxis, provided the company supplies it under its commercial arrangement. The first national UK audit (Dorr et al., Allergy 2023; 16 centres, 62 patients, most previously on C1-inhibitor prophylaxis) found total monthly attacks fell 87.7% at 6 months and 93.5% at 12 months from a baseline mean of 7.2 a month, with severe attacks down 92.1% and 94.1%, in line with the 86.8% reduction seen on two-weekly dosing in the HELP trial.
Berotralstat (Orladeyo, BioCryst) has carried a NICE recommendation since TA738 (20 October 2021), for people aged 12 and over with at least 2 attacks a month, subject to a stop rule under which treatment ends if attacks have not fallen by at least 50% after 3 months. It has been NHS-available for several years, well past the Named Patient Programme that preceded its appraisal. Its oral dosing offers a real convenience advantage over lanadelumab's four-weekly subcutaneous injection, though the two agents' evidence bases are not directly comparable: the APeX-2 trial showed a 44% attack-rate reduction versus placebo, against the 87.7% six-month reduction in the UK lanadelumab audit. NICE's positive recommendation reflects a confidential commercial arrangement alongside the stop-rule safeguard, with the NHS acute-therapy cost offset (C1 inhibitor and icatibant rescue costs of £30,000–£80,000 a year in inadequately prophylaxed patients) forming part of the ongoing economic case for both agents.
UK HAE agent NICE and NHS status
| Drug (Brand / INN) | NICE HTA Route | NICE Recommendation & PAS | NHS Commissioning Channel | Real-World / Trial Evidence | Key Payer Risk |
|---|---|---|---|---|---|
| Takhzyro (lanadelumab) | Standard Technology Appraisal (TA606, 2019) | Recommended with confidential PAS | NHS England specialised commissioning | UK national audit (Allergy 2023): 87.7% fewer attacks at 6 months, 93.5% at 12 | Dominant prophylaxis; berotralstat entry pressure on share, not price |
| Orladeyo (berotralstat) | Standard Technology Appraisal (TA738, 2021) | Recommended with confidential PAS; 3-month stop rule | NHS — accessible via HAE specialist centres | APeX-2: 44% attack reduction vs placebo — not directly comparable to lanadelumab | Oral convenience vs lanadelumab; stop-rule continuation risk for non-responders |
Sources: NICE TA606 Final Appraisal Determination (lanadelumab), 2019; Dorr et al., national UK lanadelumab audit, Allergy 2023 (doi 10.1111/all.15620); NICE TA738 Final Appraisal Determination (berotralstat), 2021; NHS BNF pricing and NHS England HAE commissioning cost data.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How has NICE TA606 lanadelumab performed against its trial data in real-world NHS use, and how does that compare to berotralstat's NICE TA738 recommendation? • TA606 real-world evidence analysis (UK audit: 87.7% and 93.5% fewer attacks at 6 and 12 months) • how the confidential commercial arrangement works • the comparator standard berotralstat's TA738 recommendation was measured against
- What did berotralstat's NICE TA738 recommendation require, and how does its 3-month stop rule manage ongoing cost-effectiveness risk? • NICE's indirect treatment comparison methodology behind TA738 • stop-rule mechanics and continuation criteria • oral-vs-SC utility trade-off as assessed by NICE
- What is the NHS economic case for HAE prophylaxis versus acute therapy costs, and how does it support NICE's cost-effectiveness modelling for both agents? • NHS acute therapy cost benchmarking (Berinert, Firazyr) against prophylaxis net cost • cost-offset modelling used in NICE TA606 and TA738's recommendations • implications for future HAE submissions
What's inside
-
1 · UK HAE Payer & Commissioning Landscape — NHS Specialist Centre Overview 4 pp
- How NHS England's commissioning policy sets who is eligible for lanadelumab: two or more clinically significant attacks a week over 8 weeks despite oral prophylaxis.
- How TA606 recommended lanadelumab under a confidential commercial arrangement.
-
2 · NICE TA606 Lanadelumab — Real-World Outcomes vs Trial Data 6 pp
- How the first national UK lanadelumab audit found an 87.7% fall in total monthly attacks at 6 months and 93.5% at 12 months, in line with the HELP trial.
- How severe attacks fell 92.1% at 6 months and 94.1% at 12 months, and attacks needing C1-inhibitor rescue fell 85.7% and 97.2%.
-
3 · Berotralstat NICE TA738 — Recommendation Criteria & Stop-Rule Mechanics 6 pp
- What TA738, dated 20 October 2021, requires: adults with 2 or more attacks a month, subject to a mandatory 3-month stop rule tied to demonstrated response.
- How the APeX-2 trial's 44% attack-rate reduction versus placebo compares, though not directly, against lanadelumab's 87.7% six-month reduction in the UK audit.
-
4 · NHS Acute Therapy Cost Offset — Berinert, Firazyr & the Prophylaxis Economic Case 4 pp
- Why C1 inhibitor and icatibant rescue costs of £30,000 to £80,000 a year in inadequately prophylaxed patients underpin the ongoing economic case for prophylaxis.
- How NHS acute-therapy cost offset modelling supported NICE's cost-effectiveness case for both lanadelumab's TA606 and berotralstat's TA738.
-
5 · NHS HAE Specialist Centre Network & Access Pathway 3 pp
- How NHS-commissioned access to lanadelumab and berotralstat runs through the specialist centres of the UK HAE clinical network.
- Why berotralstat's oral dosing offers a convenience advantage over lanadelumab's four-weekly subcutaneous injection within that same access pathway.
-
6 · Devolved Nations — Scotland (SMC) and Wales (AWMSG) Divergence Risk 3 pp
- How Scotland's SMC and Wales's AWMSG positions on lanadelumab and berotralstat are assessed separately against NICE's TA606 precedent.
- Why devolved-nation divergence risk matters given the confidential PAS commercial arrangements underpinning both TA606 and TA738.
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx HAE Payer & HTA is built for market access, HEOR, and pricing teams navigating NICE TA606's real-world outcomes and berotralstat's NICE TA738 recommendation in the UK HAE market. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, payer focus (NICE TA, PAS, NHS commissioning), and commercial question.
- 2. Scoping callAXLRx analyst confirms payer scope, NICE appraisal analysis, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
This assessment is built from NICE's published Technology Appraisal documentation, the national UK lanadelumab audit (Allergy 2023), and NHS commissioning cost benchmarks for prophylaxis and acute HAE therapy.
Key sources: NICE TA606 Final Appraisal Determination (lanadelumab), 2019; Dorr et al., national UK lanadelumab audit, Allergy 2023 (doi 10.1111/all.15620); NICE TA738 Final Appraisal Determination (berotralstat), 2021; NHS BNF acute-therapy pricing; NHS England HAE commissioning cost data. Devolved-nation positions (Scotland's SMC, Wales's AWMSG) are assessed separately against NICE's TA606 precedent.
- NICE TA606 recommendation and PAS status verified against the NICE TA606 Final Appraisal Determination, 2019
- Real-world attack-reduction figures checked against the national UK lanadelumab audit, Dorr et al., Allergy 2023 (doi 10.1111/all.15620)
- Berotralstat's NICE recommendation verified against the NICE TA738 Final Appraisal Determination, 2021
- NHS acute-therapy cost benchmarks verified against NHS BNF pricing and NHS England HAE commissioning cost data
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only: the NICE appraisals for lanadelumab and berotralstat, national UK lanadelumab audit data (Allergy 2023), NHS formulary acute-therapy pricing, and NHS England commissioning cost data. No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered assessment.
Customisation Can I tailor the assessment to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target geography, key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions, such as additional payer markets, pipeline agent profiles, or country-specific deep-dives, can be added to any standard assessment. Commission via the intake form to start.